Medchemexpress LLC Erk1/2 inhibitor 2 (ASTX-029) | 2095719-92-7 | >98.0% | 584.04 g/mol | C29H31ClFN5O5 | 25MG

Supplier:  Medchemexpress LLC HY12628825MG

ASTX029 is a dual-mechanism extracellular signal-regulated kinase (ERK) 1/2 inhibitor developed as a clinical candidate. It inhibits ERK catalytic activity and ERK phosphorylation, with reported ERK2 IC50 ≈ 2.7 nM, and has demonstrated antineoplastic activity in preclinical models and early clinical evaluation. Supplied as a crystalline solid for research use, typical vendor-reported purity is ≥98% (CAS 2095719-92-7).

• Potent dual-mechanism ERK inhibitor with low-nanomolar potency.
• Inhibits both catalytic activity and phosphorylation of ERK.
• Demonstrated antineoplastic activity in preclinical and early clinical studies.
• Supplied as a crystalline solid suitable for in vitro and in vivo formulation.
• Typical purity ≥98% by vendor testing.
• CAS number 2095719-92-7 and molecular weight ≈584.04 g/mol.
• For research use only; not for human therapeutic use.

Catalog No. 50-002-36428